title: [Cardiovascular diseases in patients with rheumatoid arthritis during long-term methotrexate therapy].
abstract: OBJECTIVE
  To compare the prevalence of risk factors, clinical and subclinical manifestations of cardiovascular diseases (CVD) and their complications in methotrexate (MT)-treated and untreated patients with rheumatoid arthritis.
  
  
  METHODS
  The investigation enrolled 193 patients (168 women and 25 men) less than 60 years of age (mean age 49 [44; 53] years) with RA. The patients were divided into 2 groups: 1) 69 patients who received MT in a dose of 15.1 [10.2; 21] mg/week for at least 12 months (mean disease duration 25 [18; 48] months); 2) 124 patients who did not take MT. The patient groups were matched for age, gender, disease duration, RA activity, and the rate of rheumatoid factor (RF) seropositivity and extraarticular manifestations.
  
  
  RESULTS
  Dyslipidemia was significantly less frequently identified in MT-treated patients (35/69 or 51%) than in MT-untreated ones (85/124 or 69%; p = 0.01). The serum from the patients treated with MT exhibited higher high-density lipoprotein cholesterol concentrations ((1.8 [0.9; 2.0] mmol/l) than in those untreated with MT (1.2 [1.0; 1.6] mmol/l; p = 0,047). In Group 1, hypertension (49%) and diabetes mellitus (3%) were slightly rare than in Group 2 (62 and 13%, respectively; p > 0.05). Carotid atherosclerotic plaques were found in 19 and 16% and intima-media thickness (IMT) enlargement was seen in 53 and 56% of the patients in Groups 1 and 2, respectively. Silent myocardial ischemia was diagnosed in every 10 patients; heart disease (exertional angina, myocardial infarction) was in every 5 patients in both groups. Aortocoronary bypass surgery was performed in 2 (3%) patients from those who received MT and had experienced MI and in one (1.6%) patient from the MT-untreated group.
  
  
  CONCLUSIONS
  Long-term MT therapy was associated with the lower rate of dyslipidemia, but it failed to affect the incidence of CVD in patients with RA.
authors.forename: E V
authors.initials: EV
authors.lastname: Gerasimova
authors.forename: T V
authors.initials: TV
authors.lastname: Popkova
authors.forename: D S
authors.initials: DS
authors.lastname: Novikova
authors.forename: E L
authors.initials: EL
authors.lastname: Nasonov
mesh_terms: D000328:Adult; D000367:Age Factors; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D002318:Cardiovascular Diseases / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology; D059168:Carotid Intima-Media Thickness; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D015994:Incidence; D008075:Lipoproteins, HDL / Q000097:blood*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D062072:Patient Acuity; D015995:Prevalence; D012217:Rheumatoid Factor / Q000097:blood; D012307:Risk Factors; D012426:Russia / Q000453:epidemiology; D012737:Sex Factors; D013995:Time
chemical_list: D018501:Antirheumatic Agents; D008075:Lipoproteins, HDL; D012217:Rheumatoid Factor; D008727:Methotrexate